摘要
目的 探讨肿瘤标志物联合检测在良、恶性胸腔积液鉴别诊断中的临床意义。方法 采集有胸腔积液患者的血清及胸水样本各 79例 ,其中恶性胸腔积液患者 35例 ,良性胸腔积液患者 4 4例 ,用免疫放射法检测其血清及胸水CEA、CA15 3、SCC和CY2 11的含量。结果 恶性胸水组血清CEA、CA15 3、SCC和CY2 11的阳性率分别为 5 8.82 %、70 .5 9%、9.0 9%和 5 4 .2 0 % ,胸水CEA、CA15 3、SCC和CY2 11的阳性率分别为 75 .76 %、70 .6 7%、2 5 .93%和 96 .6 7% ,其中 ,肿瘤标志物CEA、CA15 3和CY2 11血清及胸水的阳性率明显高于良性胸腔积液组 (P <0 .0 2 ) ;两组含量的检测亦得出相似的结果。联合检测血清CA15 3+CY2 11,其诊断恶性胸腔积液的敏感度为 94 .2 8% ,特异度为 76 .93%。结论 肿瘤标志物CEA、CA15 3和CY2 11的联合检测 ,对胸腔积液的鉴别诊断有较好的临床价值 ,联合方式以CA15 3+CY2 11为佳。
Objective To study the clinical significance of tumor markers combined assay in the differential diagnosis of. pleural effusion. Methods 79 serum and hydrothorax samples were collected from 79 in-patients with pleural effusion. Among them, 35 patients were suffered with malignant pleural effusion and 44 patients with benign pleural effusion. The concentration of CEA, CA153, SCC and CY211 was determined by immunoradiometric assay. Results In malignant pleural effusion group, the positive rates of serum CEA, CA153, SCC and CY211 were 58.82%?70.59%?9.09% and 54.20% respectively, the positive rates of hydrothorax CEA, CA153, SCC and CY211 were 75.76%?70.67%?25.93% and 96.67% respectively. Among them,CEA,CA153 and CY211 in malignant group were significantly higher than that in benign pleural effusion group ( P <0.02).So as did of the concentration. The sensitivity of combined assay with serum CA153+CY211 in diagnosing malignant pleural effusion was 94.28%, with the specificity of 76.93%. Conclusion Tumor markers of CEA,CA153 and CY211 have high clinical values in the differential diagnosis of pleural effusion. The combined assay with CA153+CY211 is recommended.
出处
《肿瘤》
CAS
CSCD
北大核心
2002年第4期322-324,共3页
Tumor
